Pharmacogenetic correlates of clinical benefit from gemcitabine and platinum in patients with advanced bladder cancer.

被引：0
|
作者：
Castro, M
Neumann, A
Konichezky, M
Danenberg, K
Stemmer, S
Wood, CR
机构：
[1] CR Wood Canc Ctr, Glens Falls, NY USA
[2] Rabin Med Ctr, Petah Tiqwa, Israel
[3] Response Genet Inc, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3202
引用
收藏
页码：244S / 244S
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetic study of the novel platinum agent ZD0473 in combination with gemcitabine: A phase I study in patients with advanced cancer.
    O'Dwyer, PJ
    Stevenson, JP
    Redlinger, M
    Sun, W
    Giantonio, B
    Hahn, S
    Algazy, K
    Burnite, M
    Garcia-Vargas, J
    Roberts, DW
    Oliver, R
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3750S - 3750S
  • [22] Clinical benefit of gemcitabine-cisplatin in advanced non-small cell lung cancer elderly patients
    Lippe, P
    Silva, RR
    Giuliodori, L
    Monterubbianesi, MC
    Mattioli, R
    Massacesi, C
    Cascinu, S
    Tummarello, D
    Cellerino, R
    ANTICANCER RESEARCH, 2002, 22 (2B) : 1053 - 1059
  • [23] Randomized controlled trial of gemcitabine in combination with UFT versus gemcitabine alone in patients with advanced pancreatic cancer.
    Ohkawa, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 346S - 346S
  • [24] Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
    Wang-Gillam, Andrea
    Lockhart, A. Craig
    Tan, Benjamin R.
    Suresh, Rama
    Lim, Kian-Huat
    Ratner, Lee
    Morton, Ashley
    Huffman, Jess
    Marquez, Samantha
    Boice, Nicolas
    DeNardo, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [25] Phase II study of gemcitabine, capecitabine and cisplatin in patients with advanced pancreatic cancer.
    Chang, HM
    Kim, TW
    Ahn, JH
    Ryu, MH
    Lee, JS
    Kim, WK
    Kang, YK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 368S - 368S
  • [26] Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
    Wang-Gillam, Andrea
    Lockhart, A. Craig
    Tan, Benjamin R.
    Suresh, Rama
    Lim, Kian-Huat
    Ratner, Lee
    DeNardo, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] On a possible mechanism of platinum resistance development in patients with advanced ovarian cancer.
    Zhukova, Galina V.
    Ulianova, Elena P.
    Yakubova, Darya Yu.
    Sagakyants, Aleksandr B.
    Menshenina, Anna P.
    Moiseenko, Tatiana I.
    Verenikina, Ekaterina V.
    Zlatnik, Elena Yu
    Chalabova, Tatiana G.
    Pustovalova, Alla V.
    Kit, Oleg I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17549 - E17549
  • [28] An institutional analysis of gemcitabine and capecitabine for advanced biliary cancer.
    Gandhi, Shipra
    Gabriel, Emmanuel M.
    Attwood, Kristopher
    Ma, Wen Wee
    Kuvshinoff, Boris W.
    Hochwald, Steven N.
    Iyer, Renuka V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [29] Gemcitabine in gallbladder cancer: clinical benefit assessment
    Gallardo, J
    Rubio, B
    Fodor, M
    Ahumada, M
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 305 - 305
  • [30] Clinical benefit of continuing apatinib beyond progression in advanced or metastatic gastric cancer.
    Qin, Shukui
    Wen, Lu
    Wang, Junsheng
    Deng, Wenying
    Zhang, Guifang
    Jia, Tongfu
    Ba, Yi
    Zhong, Haijun
    Yang, Jianwei
    Lin, Xiaoyan
    Bai, Yu-Xian
    He, Yifu
    Xie, Zhong
    Yi, Tienan
    Wu, Xiangyuan
    Ye, Feng
    Liu, Likun
    Huang, Yong
    Wang, Mei
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345